{
    "root": "19368778-01f6-4492-b454-ee47e4366245",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Rivaroxaban"
    },
    "value": "20250520",
    "ingredients": [
        {
            "name": "RIVAROXABAN",
            "code": "9NDF7JZ4M3"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "rivaroxaban tablets factor xa inhibitor indicated : • reduce risk stroke systemic embolism nonvalvular atrial fibrillation ( 1.1 ) • treatment deep vein thrombosis ( dvt ) ( 1.2 ) • treatment pulmonary embolism ( pe ) ( 1.3 ) • reduction risk recurrence dvt pe ( 1.4 ) • prophylaxis dvt , may lead pe patients undergoing knee hip replacement surgery ( 1.5 ) • prophylaxis venous thromboembolism ( vte ) acutely ill medical patients ( 1.6 ) • reduce risk major cardiovascular events patients coronary artery disease ( cad ) ( 1.7 ) • reduce risk major thrombotic vascular events patients peripheral artery disease ( pad ) , including patients recent lower extremity revascularization due symptomatic pad ( 1.8 ) • treatment vte reduction risk recurrent vte pediatric patients birth less 18 years ( 1.9 ) • thromboprophylaxis pediatric patients 2 years older congenital heart disease fontan procedure ( 1.10 )",
    "contraindications": "• nonvalvular atrial fibrillation : 15 20 mg , daily food ( 2.1 ) • treatment dvt and/or pe : 15 mg orally twice daily food first 21 days followed 20 mg orally daily food remaining treatment ( 2.1 ) • reduction risk recurrence dvt and/or pe patients continued risk dvt and/or pe : 10 mg daily without food , least 6 months standard anticoagulant treatment ( 2.1 ) • prophylaxis dvt following hip knee replacement surgery : 10 mg orally daily without food ( 2.1 ) • prophylaxis vte acutely ill medical patients risk thromboembolic complications high risk bleeding : 10 mg daily , without food , hospital hospital discharge total recommended duration 31 39 days ( 2.1 ) • cad pad : 2.5 mg orally twice daily without food , combination aspirin ( 75-100 mg ) daily ( 2.1 ) • pediatric patients : dosing recommendations full prescribing information ( 2.2 )",
    "warningsAndPrecautions": "rivaroxaban tablets available strengths packages listed : • 2.5 mg tablets light yellow colour , circular , biconvex , film coated tablets debossed “ j 7 ” one side plain side . tablets supplied packages listed : ndc 33342-488-09 bottle containing 60 tablets ndc 33342-488-57 bottle containing 180 tablets ndc 33342-488-98 blister package containing 60 tablets ( 10 blister cards containing 6 tablets ) store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . keep reach children .",
    "adverseReactions": "rivaroxaban tablets contraindicated patients : • active pathological bleeding [ ( 5.2 ) ] • severe hypersensitivity reaction rivaroxaban tablets ( e.g . , anaphylactic ) [ ( 6.2 ) ]",
    "indications_original": "Rivaroxaban tablets are a factor Xa inhibitor indicated: • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) • for treatment of deep vein thrombosis (DVT) ( 1.2 ) • for treatment of pulmonary embolism (PE) ( 1.3 ) • for reduction in the risk of recurrence of DVT or PE ( 1.4 ) • for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) • for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) • for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )",
    "contraindications_original": "• Nonvalvular Atrial Fibrillation : 15 or 20 mg, once daily with food ( 2.1 ) • Treatment of DVT and/or PE : 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment ( 2.1 ) • Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE : 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment ( 2.1 ) • Prophylaxis of DVT Following Hip or Knee Replacement Surgery : 10 mg orally once daily with or without food ( 2.1 ) • Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding : 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days ( 2.1 ) • CAD or PAD: 2.5 mg orally twice daily with or without food, in combination with aspirin (75-100 mg) once daily ( 2.1 ) • Pediatric Patients: See dosing recommendations in the Full Prescribing Information ( 2.2 )",
    "warningsAndPrecautions_original": "Rivaroxaban Tablets are available in the strengths and packages listed below: • 2.5 mg tablets are Light yellow colour, circular, biconvex, film coated tablets debossed with “J 7” on one side and plain on the other side. The tablets are supplied in the packages listed:  NDC 33342-488-09       Bottle containing 60 tablets NDC 33342-488-57       Bottle containing 180 tablets NDC 33342-488-98  Blister package containing 60 tablets (10 blister cards containing 6 tablets each)\n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Keep out of the reach of children.",
    "adverseReactions_original": "Rivaroxaban tablets is contraindicated in patients with:  • active pathological bleeding [see Warnings and Precautions (5.2)]\n                      • severe hypersensitivity reaction to Rivaroxaban tablets (e.g., anaphylactic reactions) [see Adverse Reactions (6.2)]"
}